Drugs / UC-781
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00446979 | Jun → Oct 2007 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 1 | NCT00408538 | Dec 2006 → Apr 2008 | HIV infectious disease | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 1 | NCT00441909 | Apr 2006 → Apr 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00385554 | — | HIV infectious disease | Centers for Disease Control and Prevention | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00132444 Comparator | Oct 2005 → Dec 2008 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UC-781 | “We report the first-in-field Phase 1 trial of a rectally-applied, vaginally-formulated microbicide gel with the RT-inhibitor UC781 measuring clinical and mucosal safety,...” PMID 21969851 ↗ Sep 20116“Safety Study of UC-781 Vaginal Microbicide” NCT00446979 ↗ |
| Action | Inhibit | “the RT-inhibitor UC781” PMID 21969851 ↗ Sep 2011 |
| Modality | Small molecule | — CHEMBL54893 ↗ |
| Route | Other | “0.1% UC-781 gel and 0.25% UC-781 gel administered intravaginally twice-daily for 14 days” NCT00132444 ↗ |